International Approaches to Regulation of Medicinal Products Containing Viable Human Cells

The intensive development of cellular technologies stipulates the introduction at the global level of medicinal products based on viable human cells, which in most countries are referred to as biomedical cell products. The authors conducted a comparative analysis of the regulatory framework in different countries and determined special aspects of regulation of cell therapy products (analogues of biomedical cell products). Some countries have mechanisms for priority review of cell therapy products for marketing authorization, such as accelerated assessment, accelerated approval, or conditional marketing authorisation. These mechanisms are currently absent in Russia, because of the novelty of the regulatory framework, and the biological properties of innovative cell products. Biomedical cell products are regarded as a separate class of medicinal products in Russia, they are not treated as biologicals and are regulated by the Federal Law No. 180-FZ «On Biomedical Cell Products» of June 23, 2016. The main difference in regulation of cell-based products in the Russian Federation is the principle of unified requirements for marketing authorisation of autologous, allogeneic, and combined biomedical cellular products, and the absence of the «hospital exemptions» mechanism that exists in many countries. This mechanism allows prescription and use of personalised autologous medicines produced in the laboratory of a medical institution for a particular patient.

1. Распоряжение Правительства Российской Федерации от 28 февраля 2018 г. № 337-р «Об утверждении плана мероприятий («дорожной карты») «Развитие биотехнологий и генной инженерии» на 2018–2020 годы». [Resolution of the Government of the Russian Federation of February 28, 2018, No. 337-r «Action plan for development of biotechnology and genetic engineering (roadmap) for 2018–2020» (In Russ.)]

2. Распоряжение Правительства Российской Федерации от 5 мая 2018 г. № 870-р «Об утверждении плана мероприятий («дорожной карты») по совершенствованию законодательства и устранению административных барьеров в целях обеспечения реализации плана мероприятий («дорожной карты») Национальной технологической инициативы по направлению «Хелснет» [Resolution of the Government of the Russian Federation of May 5, 2018, No. 870-r «Action plan for development and implementation of the «Healthnet» National technological initiative (roadmap)» (In Russ.)]

3. Перечень медицинских технологий, разрешенных к применению в медицинской практике на 30 декабря 2011 г. [List of medicinal technologies, authorized for medical practice for December 30, 2011 (In Russ.)] Available from: http://www.roszdravnadzor.ru/archive/documents/12545

4. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and Amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union. 2007;50(L 324):121–37. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf

5. Part 1271 Human cells, tissues, and cellular and tissuebased products (21CFR1271). Code of Federal Regulations Title 21. FDA; 2017.

6. Tiedemann G, Sethe S. Regulatory framework for cell and tissue based therapies in Europe. In: Steinhoff G, ed. Regenerative medicine — from protocol to patient. 4. Regenerative therapies I. 3rd ed. Switzerland: Springer; 2016. P. 21–33.

7. Зубов ДА, Васильев РГ, Оксимец ВМ, Родниченко АЕ, Злацкая АВ, Губарь ОС, Гордиенко ИМ. Результаты применения ткане-инженерного эквивалента кости: трехлетний период наблюдений. Материалы III национального конгресса по регенеративной медицине. Гены и Клетки. 2017;XII(3):100–1. [Zubov DA, Vasyliev RG, Oksimets VM, Rodnichenko AE, Zlatskaya AV, Gubar OS, Gordienko IM. The results of the application of tissue-engineering equivalent of the bone: a three-year observation period. Materials of the 3rd national congress on regenerative medicine. Genes and Cells. 2017;XII(3):100–1 (In Russ.)]

8. Васильев РГ, Грицык ВФ, Литвинова ЛС, Родниченко АЕ, Губарь ОС, Шуплецова ВВ и др. Постнатальные мультипотентные стволовые/прогениторные клетки — производные нервного гребня: трансляция в клиническую практику. Материалы III национального конгресса по регенеративной медицине. Гены и Клетки. 2017;XII(3):59. [Vasyliev RG, Gritsyk VF, Litvinova LS, Rodnichenko AE, Gubar OS, Shupletsova VV, et al. Postnatal Multipotent stem/progenitor cells — derivatives of nerve crest: translation into clinical practice. Materials of the 3rd national congress on regenerative medicine. Genes and Cells. 2017;XII(3):59 (In Russ.)]

9. Guidance for human somatic cell therapy and gene therapy. U.S. Department of health and human services. FDA. CBER; 1998.

10. Guideline on human cell-based medicinal products (EMEA/CHMP/410869/2006). EMA; 2007.

11. 21st Century cures act. Public law 114–255. 114th Congress, December 13, 2016. Available from: https://www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf

12. Expedited Programs for regenerative medicine therapies for serious conditions. U.S. Department of health and human services. FDA. CBER; 2017.

13. European Medicines Agency guidance for applicants seeking access to PRIME scheme (EMA/191104/2015). EMA; 2018.

14. Kasai M. Regulation of regeneranive medicine in Japan. Advanced therapies workshop, centre of regulatory excellence, Duke-NUS Medical School, 17–19 July, 2017. Available from: https://teamlead.duke-nus.edu.sg/vapfiles_ocs/core/core_apec_rhsc_coe_adv_therapies_wrkshp_regulate_regenerative_meds_japan/index5.html

15. Assessment Report. Zalmoxis (EMA/CHMP/589978/2016). EMA; 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002801/WC500212588.pdf

16. Guideline on the risk-based approach according to annex I,part IV of Directive 2001/83/EC applied to advanced therapy medicinal products (EMA/CAT/CPWP/686637/2011). EMA; 2013.

17. Concept paper on the revision of the guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells (EMA/CAT/424191/2017). EMA; 2017.

18. Guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products (EMEA/149995/2008 rev. 1). EMA; 2018.

19. Ridgway AA. The regulation of cell therapy products in Canada. Biologicals. 2015.43(5):406–9. https://doi.org/10.1016/j.biologicals.2015.05.013

20. Food and drugs act (R.S.C., 1985, c. F-27). Health Canada; 2018. Available from: http://laws-lois.justice.gc.ca/eng/acts/F-27/index.html

21. Safety of human cells, tissues and organs for transplantation regulations (SOR/2007-118). Health Canada; 2018. Available from: http://laws-lois.justice.gc.ca/eng/regulations/SOR-2007-118/index.html

22. Therapeutic goods (excluded goods) Order No. 1 of 2011. Australian Government. Department of health. Therapeutic goods administration; 2011. Available from: https://www.tga.gov.au/therapeutic-goods-excluded-goods-order-no-1-2011

23. Trickett AE, Wall DM. Regulation of cellular therapy in Australia. Pathology. 2011;43(6):627–34. https://doi.org/10.1097/PAT.0b013e32834b3cfa

24. Pharmaceutical administration and regulations in Japan. Information on Japanese regulatory affairs. Regulatory information task force. Japan pharmaceutical manufacturers association; 2017. Available from: http://www.jpma.or.jp/english/parj/pdf/2017.pdf

25. Galli MC, Serabian M, eds. Regulatory aspects of gene therapy and cell therapy products: a global perspective. Advances in experimental medicine and biology 871. Springer; 2015.

26. Han E, Shin W. Regulation of cell therapy products in Korea. ISBT Science series. 2015;10(S1):129–33. https://doi.org/10.1111/voxs.12158

27. Sale of drugs act (chapter 282). Revised edition. Singapore: statutes of the republic of Singapore; 1985. Available from: http://www.hsa.gov.sg/content/dam/HSA/HPRG/Useful_Information_for_Applicants/Legislation/SALE%20OF%20DRUGS%20ACT.pdf

28. Pharmaceutical affairs act. Republic of China (Taiwan): Ministry of Health and Welfare; 2018. Available from: http://law.moj.gov.tw/Eng/LawClass/LawAll.aspx?PCODE=L0030001

29. Medical care act. Republic of China (Taiwan): Ministry of Health and Welfare; 2018. Available from: http://law.moj.gov.tw/Eng/LawClass/LawAll.aspx?PCODE=L0020021

30. Chen YC, Cheng HF, Yeh MK. Cell therapy regulation in Taiwan. Cell Transplant. 2017;26(3):483–92. https://doi.org/10.3727/096368916X693293

31. 16th ICDRA recommendations. WHO Drug Information. 2014;28(3):298–306. Available from: http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/16_ICDRA_Recommendations2014.pdf

32. Постановление Совета Министров Республики Беларусь от 28 ноября 2014 г. № 1120 «О некоторых вопросах государственной регистрации биомедицинских клеточных продуктов». [Resolution of the council of ministers of the republic of Belarus of November 28, 2014, No. 1120 «On some issues of State registration of biomedical cell products» (In Russ.)] Available from: http://pravo.by/upload/docs/op/C21401120_1417554000.pdf